Avis et décisions de la HAS
La fiche de bon usage du médicament intitulée « Xolair (omalizumab) dans le traitement de l’asthme sévère», ci-jointe, est adoptée.
Voir aussi
Avis et décisions de la HAS
17/11/2017
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
bBaXGNJYNGE7jvqv
Écouter
